Decreased Cerebral Blood Flow in Renal Transplant Recipients

Chisako Kamano, Yuichi Komaba, Osamu Sakayori, Yasuhiro Ino and Yasuo Katayama

Abstract

Objective We performed single-photon emission computed tomography (SPECT) to investigate the influence of renal transplantation on cerebral blood flow (CBF).

Patients and Methods Fifteen renal transplant recipients and twelve normal subjects underwent cerebral SPECT with N-isopropyl-\[123\]I iodoamphetamine (\[123\]I-IMP). All transplant recipients received prednisolone and cyclosporine (CyA). Regional CBF (rCBF) was measured by defining regions of interest in the cerebral cortex, deep white matter, striatum, thalamus, and cerebellum. In transplant recipients, correlations to the mean overall cortical CBF were assessed using the interval from transplantation to measurement of SPECT, as well as the serum creatinine concentration. Moreover, to investigate the influence of CyA on CBF, the correlation between mean overall cortical CBF and CyA trough concentrations was assessed.

Results In all regions, CBF in renal transplant recipients was significantly lower than in normal subjects. No significant correlation was seen between serum creatinine, interval from transplantation, or CyA trough concentrations and mean overall cortical CBF.

Conclusion Renal transplant recipients demonstrated a decrease in CBF, that can have an associated secondary pathology. Therefore, renal transplant recipients may benefit from post-operative MRI or CT.

Materials and Methods

Subjects We studied 15 Japanese renal transplant recipients (4 males, 11 females) ranging in age from 29 to 51 years (mean ± SD, 39.7 ± 9.1) and 12 normal volunteer subjects (6 males, 6 females; hematocrit, 41.7 ± 9.34%; systolic blood pressure/ diastolic blood pressure, 125.8 ± 12.3/75.8 ± 9.0 mmHg ) of similar age (24 to 59 years; mean ± SD, 46.5 ± 11.1 years). Full informed consent was obtained from both the recipients and normal subjects before the initiation of the study. Serum creatinine concentrations in the recipients was 2.1 ± 1.2 mg/dl (mean ± SD). Fourteen renal transplant recipients had hypertension and were maintained on oral antihypertensive agents. Recipients with diabetes mellitus were excluded. Blood pressure was well controlled in all recipients. Tables 1 and 2 summarize characteristics of the recipients, all of whom were receiving immunosuppressive agents.

SPECT imaging and measurement

Recipients and normal subjects underwent SPECT in a resting state. Their ears were not plugged, but their eyes were closed. The method described by Iida et al (7) was used to measure regional (r) CBF. The SPECT scanner was a Headtome-SET080 (Shimadzu, Kyoto), which has a ring col-
### Table 1. Renal Transplant Recipients Profiles

<table>
<thead>
<tr>
<th>Case</th>
<th>Sex</th>
<th>Age</th>
<th>Interval from transplantation to CBF (month)</th>
<th>Period of hemodialysis before transplantation (month)</th>
<th>CyA trough concentrations (ng/ml)</th>
<th>Steroid (mg/day)</th>
<th>Other drug (mg/day)</th>
<th>Serum creatinine (mg/dl)</th>
<th>Hematocrit (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>F</td>
<td>33</td>
<td>129</td>
<td>16</td>
<td>125</td>
<td>60</td>
<td>PSL 15</td>
<td>5.5</td>
<td>20.5</td>
</tr>
<tr>
<td>2</td>
<td>F</td>
<td>50</td>
<td>126</td>
<td>12</td>
<td>150</td>
<td>44</td>
<td>PSL 10</td>
<td>3.7</td>
<td>22.5</td>
</tr>
<tr>
<td>3</td>
<td>F</td>
<td>51</td>
<td>128</td>
<td>4</td>
<td>150</td>
<td>55</td>
<td>PSL 7.5</td>
<td>2.2</td>
<td>33.9</td>
</tr>
<tr>
<td>4</td>
<td>M</td>
<td>25</td>
<td>117</td>
<td>0</td>
<td>150</td>
<td>47</td>
<td>PSL 5</td>
<td>2.0</td>
<td>34.5</td>
</tr>
<tr>
<td>5</td>
<td>F</td>
<td>50</td>
<td>86</td>
<td>24</td>
<td>75</td>
<td>74</td>
<td>Methyl PSL 4</td>
<td>2.2</td>
<td>33.0</td>
</tr>
<tr>
<td>6</td>
<td>M</td>
<td>38</td>
<td>80</td>
<td>32</td>
<td>150</td>
<td>136</td>
<td>PSL 10</td>
<td>2.2</td>
<td>44.2</td>
</tr>
<tr>
<td>7</td>
<td>F</td>
<td>42</td>
<td>88</td>
<td>15</td>
<td>100</td>
<td>60</td>
<td>Methyl PSL 4</td>
<td>1.3</td>
<td>33.6</td>
</tr>
<tr>
<td>8</td>
<td>M</td>
<td>50</td>
<td>57</td>
<td>14</td>
<td>100</td>
<td>78</td>
<td>PSL 7.5</td>
<td>2.0</td>
<td>38.8</td>
</tr>
<tr>
<td>9</td>
<td>M</td>
<td>29</td>
<td>8</td>
<td>3</td>
<td>350</td>
<td>136</td>
<td>PSL 20</td>
<td>2.6</td>
<td>29.4</td>
</tr>
<tr>
<td>10</td>
<td>F</td>
<td>43</td>
<td>99</td>
<td>36</td>
<td>125</td>
<td>52</td>
<td>Methyl PSL 4</td>
<td>1.1</td>
<td>30.7</td>
</tr>
<tr>
<td>11</td>
<td>F</td>
<td>30</td>
<td>35</td>
<td>8</td>
<td>150</td>
<td>71</td>
<td>PSL 5</td>
<td>1.5</td>
<td>38.3</td>
</tr>
<tr>
<td>12</td>
<td>F</td>
<td>51</td>
<td>73</td>
<td>30</td>
<td>100</td>
<td>45</td>
<td>PSL 10</td>
<td>1.9</td>
<td>38.5</td>
</tr>
<tr>
<td>13</td>
<td>F</td>
<td>34</td>
<td>115</td>
<td>8</td>
<td>100</td>
<td>123</td>
<td>PSL 15</td>
<td>1.2</td>
<td>38.4</td>
</tr>
<tr>
<td>14</td>
<td>F</td>
<td>39</td>
<td>121</td>
<td>0</td>
<td>150</td>
<td>368</td>
<td>PSL 5</td>
<td>1.1</td>
<td>33.9</td>
</tr>
<tr>
<td>15</td>
<td>F</td>
<td>31</td>
<td>16</td>
<td>9</td>
<td>200</td>
<td>73</td>
<td>PSL 15</td>
<td>1.2</td>
<td>40.3</td>
</tr>
</tbody>
</table>


### Table 2. Renal Transplant Recipients Profiles

<table>
<thead>
<tr>
<th>Case</th>
<th>Hypertension</th>
<th>Blood pressure systolic/diastolic (mmHg)</th>
<th>Antihypertensive drugs</th>
<th>Calcium blocker</th>
<th>ACE inhibitor</th>
<th>α blocker</th>
<th>β blocker</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>+</td>
<td>140/80</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>2</td>
<td>+</td>
<td>170/100</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>3</td>
<td>+</td>
<td>146/96</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>4</td>
<td>+</td>
<td>120/70</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>5</td>
<td>+</td>
<td>130/80</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>6</td>
<td>+</td>
<td>140/90</td>
<td>+</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>7</td>
<td>+</td>
<td>150/90</td>
<td>+</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>8</td>
<td>+</td>
<td>110/60</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>9</td>
<td>+</td>
<td>160/90</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>10</td>
<td>+</td>
<td>130/80</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>11</td>
<td>+</td>
<td>136/80</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>12</td>
<td>+</td>
<td>150/80</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>13</td>
<td>+</td>
<td>130/80</td>
<td>+</td>
<td>–</td>
<td>+</td>
<td>–</td>
<td>–</td>
</tr>
<tr>
<td>14</td>
<td>+</td>
<td>130/70</td>
<td>–</td>
<td>–</td>
<td>+</td>
<td>+</td>
<td>–</td>
</tr>
<tr>
<td>15</td>
<td>–</td>
<td>120/80</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
<td>–</td>
</tr>
</tbody>
</table>

limator consisting of 96 rectangular NaI detectors. Spatial resolution at the center of view was 8.5 mm in full width at half-maximum activity. Slice thickness was 5 mm. As a tracer, 222 MBq of N-isopropyl-p-[123I] iodoamphetamine (123I-IMP) was injected intravenously. Blood was sampled from the left brachial artery to measure radioactivity with a scintillation counter 10 minutes after initiation of tracer injection. Scanning was initiated 25 minutes after injection of 123I-IMP, and continued for 30 minutes. A Butterworth filter of order 4, with a ramp and a cutoff frequency of 2.2 cycle cm⁻¹, was used. Scatter correction was not performed, while attenuation correction was performed assuming an elliptical brain outline approximating a circle.

Images reflecting CBF were created by the SPECT autoradiographic method (7). CBF images in 128 × 128 mode were obtained to represent six slices of brain parallel to the orbitomeatal plane (OM); (OM+20, OM+30, OM+40, OM+50, OM+65, and OM+80 mm). Placement of circular regions of
interest (ROI) was performed as described in previous studies (8–10). One ROI, 22 mm in diameter was placed in each cerebellar hemisphere, while 66 ROI approximately 13 mm in diameter were placed in cerebral cortical and subcortical areas (Fig. 1). Mean rCBF values in frontal, temporal, parietal, and occipital cortex, deep white matter, thalamus, striatum, and cerebellar hemispheres were obtained in each recipient and normal subject.

Statistical methods
In each region, rCBF was compared by the unpaired t test with Bonferoni correction between recipients and normal subjects. The significance threshold was set at $P = 0.05$. Additionally, in recipients, Spearman rank correlation coefficients were calculated between overall mean cortical CBF and each of two variables; the interval from transplantation to CBF measurement, period of hemodialysis before transplantation, blood pressure, hematocrit, and serum creatinine concentration. CyA trough concentrations were monitored in whole blood, allowing for analysis of the correlation between CyA trough concentrations and overall mean cortical rCBF using Spearman rank correlation coefficients. Furthermore, we also analyzed the correlation between CyA trough levels and rCBF in frontal, temporal, parietal, and occipital cortices, deep white matter, thalamus, striatum, and cerebellar hemispheres, respectively, using Spearman rank correlation coefficients.

Results
Values for rCBF in frontal, temporal, parietal, and occipital cortices, deep white matter, thalamus, striatum, and cerebellar hemispheres in renal transplant recipients were significantly lower than in normal subjects. (*$P < 0.001$, the paired-t test with Bonferoni correction).
lower than in normal subjects ($P<0.001$) (Fig. 2). In transplant recipients, mean CBF in the frontal cortex was reduced to 74.9% of normal; 77.8%, in the temporal cortex; 73.1%, in the parietal cortex; 72.2%, in the occipital cortex; 78.6%, in the deep white matter; 69.8%, in the thalamus; 78.6%, in the striatum; and 74.3%, in the cerebellum. CBF images also revealed reduction of each rCBF in renal transplant recipients compared with normal subjects (Fig. 3).

No significant correlation was noted between the interval from transplantation to CBF measurement, period of hemodialysis before transplantation, systolic blood pressure, diastolic blood pressure, value of hematocrit, or serum creatinine concentration and mean overall cortical CBF in renal transplant recipients. There was also no significant correlation between overall mean cortical rCBF and CyA trough levels. Figure 4 illustrates CyA trough levels vs overall cortical CBF. There was no significant correlation between CyA trough levels and each rCBF in frontal, temporal, parietal, and occipital cortices, deep white matter, thalamus, striatum, and cerebellar hemispheres in renal transplant recipients.

**Discussion**

We studied rCBF in renal transplant recipients and normal
It is known that CyA reduces deformability of erythrocytes and reduces renal blood flow in rats (22). Thus, administration of mals. Intracoronary injection of CyA decreases coronary arte-

tion in renal function. Moreover, the causative factor was not related to the post transplantation interval, which showed no correlation with CBF. PET study demonstrated that long-term HD is one of the factors for decreased CBF (11). However, there was no correlation between the overall mean CBF and the period of hemodialysis before transplantation in the present study. Because of a short period of hemodialysis before transplantation, the HD duration may not influence CBF. In spite of a short HD duration, CBF was significantly decreased in renal transplant recipients compared with normal subjects.

Fourteen renal transplant recipients had hypertension and were maintained on oral antihypertensive agents with good control. It is known that chronic hypertension shifts both the lower and upper limits of autoregulation towards higher pressures (12–15) and this hypertensive adaptation of CBF autoregulation is reversible with chronic hypertensive agents (16, 17). Therefore, an influence of the antihypertensive treatment on CBF was ruled out.

All of the renal transplant recipients in the present study received prednisolone and cyclosporin A (CyA). CyA is widely used, as a powerful immunosuppressive agent to enhance the long-term survival of engrafted tissue (18, 19). However, CyA is reported to influence organ blood flow in experimental animals. Intracoronary injection of CyA decreases coronary arterial blood flow in dogs (20), and hepatic blood flow in pigs is decreased significantly by intravenous CyA infusion (21). CyA reduces renal blood flow in rats (22). Thus, administration of CyA can reduce blood flow in a variety of host organs. However, no significant correlation was found between the CyA trough concentrations and mean cortical rCBF. Unfortunately we did not measure the CyA concentration during SPECT scan; instead, we monitored CyA trough concentrations as is conventional to ensure maintenance of engrafted tissue. Therefore, CyA still remains as a potential cause of reduced CBF in renal transplant patients.

It is known that CyA reduces deformability of erythrocytes and induces endothelial-dependent vasoconstriction. Microcirculation is greatly affected by deformability of erythrocytes, and deformability of erythrocytes is a major determinant of resistance to flow. In vivo experiments with erythrocytes demonstrated that CyA causes a reduction in deformability of erythrocytes in association with an influx of calcium (23). Previous studies demonstrated that the reduction in deformability of erythrocytes can be induced merely by elevating intracellular calcium (24, 25). Clinical studies also demonstrated a higher erythrocyte calcium content in patients receiving CyA, when compared to healthy control subjects (26); furthermore, erythrocyte deformability is reduced in transplant recipients treated with CyA (27). Taken together, CyA is thought to influence erythrocitic rheologic properties, especially deformability, by increasing the intracellular calcium ion concentration. Administration of CyA also is reported to induce endothelial-dependent vasoconstriction (28). Exposure of cultured human endothelial cells to CyA has been reported to induce production and secretion of endothelin-1 (ET-1) (29–31), which has strong vasoconstrictive effects. Systemic infusion of a high concentration of CyA in animals results in marked elevation of ET-1 (32). Moreover, recipients treated orally with CyA have higher plasma ET-1 concentrations than untreated individuals (33). Experimentally, a similar increase in plasma ET-1 is caused not by activation of the endothelin-converting enzyme-1 gene but by increased prepro-ET-1 (pp-ET-1) mRNA expression, following intrarenal CyA injection (34). ET-1 injected directly into the cerebral circulation causes a reduction in CBF (35). Therefore, one possible reason for CyA-associated decreases in CBF is elevation of plasma ET-1. Thus, we must suspect an influence of CyA on CBF (caused by a CyA-induced decrease in deformability of erythrocytes, an increase in endothelial-dependent vasoconstriction, or both) in renal transplant patients.

We described above the influence of CyA on rheology. In the aspect of its influence on neuronal metabolism, CyA is known to induce neurotoxicity (36). A reversible posterior leuкоencephalopathy syndrome is the most serious complication of CyA. Symptoms of reversible posterior leukoencephalopathy are characterized by headache, altered mental functioning, seizures, cortical blindness, and other visual disturbances, with associated hypertension. CT nonenhancing areas of hypodensity are seen predominantly in the white matter of the occipital regions and MRI analysis demonstrates decreased signals on T1-weighted images, and hyperintense signals on T2-weighted images, in the occipital regions of patients with reversible posterior leukoencephalopathy. In the present renal transplant recipients, there was no significant correlation between CyA trough levels and rCBF in all of the investigated regions. However, it is known that neurotoxicity due to CyA can occur at normal and at high drug levels (36). Therefore, the influence of subclinical CyA neurotoxicity on CBF can not be denied because of the coupling of CBF to cerebral metabolism, although there were no symptoms, or neuroimaging findings, of reversible posterior leukoencephalopathy syndrome in the present recipients.

The presence of atherosclerosis may influence CBF in renal transplant recipients. There was a possibility of atherosclerosis in renal transplant recipients due to a variety of causes, though we did not examine the ocular fundus which would have allowed us to determine the degree of arteriosclerosis. All of the renal transplant recipients in the present study received prednisolone as well as CyA. Prednisolone induces proliferation of aortic smooth muscle cells and atherosclerosis in a gradual manner (37, 38). Administration of CyA has been reported to cause calcification in some tissues (39, 40). Canavese et al also reported a patient with worsening vascular calcifications following renal transplantation although the im-
munosuppressive regimen was not described (41). Moreover, Hofbauer et al provided a potential mechanism for CyA-induced bone loss, and the propensity of CyA to cause vascular disease (42). The hypothesis of Lindner et al of an accelerated atherosclerosis in chronic dialysis patients has been widely accepted (43). Risk factors for atherogenesis in chronically uremic patients are thought to be tensile stress, shear stress, alterations in blood flow, disturbance of lipid metabolism, disturbance of glucose metabolism, hyperhomocysteinemia, disturbance of calcium and phosphorous metabolism, cytokines, and vasoactive, endothelium-, and platelet-derived compounds (44). The increase of homocystein concentrations generally persists after successful renal transplantation (45). This implies that atherosclerosis may progress even after renal transplantation. Taken together, atherosclerosis may be brought about by various causes in renal transplant recipients. The present result can not completely deny the influence of atherosclerosis on CBF in renal transplant recipients, although no significant correlation was noted between the interval from transplantation to CBF measurement, or the period of hemodialysis before transplantation and mean overall cortical CBF in renal transplant recipients.

Conclusion

The present study revealed no significant correlation between cortical CBF and the duration of the interval from transplantation to measurement of CBF in renal transplant recipients. However, cerebral circulatory status is thought to represent continuous hypoperfusion in transplant recipients. We know of no reports of cerebral infarction following chronic cerebral hypoperfusion in transplant recipients. Therefore, follow-up MRI or CT may be necessary to detect occurrence of ischemic lesions in renal transplant recipients.

Acknowledgements: We thank Dr. Parsia A. Vagefi for his critical reading of the manuscript.

References


